Related Experiment Video

Updated: Aug 22, 2025

Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
06:29

Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19

Published on: May 25, 2022

2.4K

Evaluation of patients with antiphospholipid syndrome subsequently COVID-19 vaccinations: A retrospective cohort

Özlem Karakaş1, Abdulsamet Erden2, Berkan Armağan1

  • 1Clinic of Rheumatology, Ankara City Hospital, Ankara, Turkey.

International Journal of Rheumatic Diseases
|November 13, 2022
PubMed

Insights

COVID-19 vaccination in antiphospholipid syndrome (APS) patients showed common side effects like myalgia and malaise. Importantly, no new thrombotic events or APS flares were observed after receiving CoronaVac or BNT162b2 vaccines.

Area of Science:

  • Immunology
  • Vaccinology
  • Rheumatology

Background:

  • Antiphospholipid syndrome (APS) is an autoimmune disorder increasing thrombotic risk.
  • COVID-19 vaccines are crucial, but safety in APS patients requires specific evaluation.

Purpose of the Study:

  • To assess side effects and complications following COVID-19 vaccination in APS patients.
  • To investigate thrombotic or obstetric events post-vaccination in this cohort.

Main Methods:

  • Retrospective cohort study of 35 APS patients vaccinated with CoronaVac and/or BNT162b2.
  • Data collected via outpatient appointments and phone calls regarding adverse events.
  • Evaluation of vaccine-related thrombotic events, APS flares, and obstetric complications.

Main Results:

  • Most common adverse events were myalgia and malaise after both vaccines.
  • No new vaccine-related thrombotic events or APS flares were observed.
  • Reported adverse events in 45.0% of BNT162b2 recipients and 42.9% of CoronaVac recipients.

Conclusions:

  • COVID-19 vaccination appears safe in APS patients regarding thrombotic events and disease flares.
  • Common side effects like myalgia and malaise are manageable.
  • Further large-scale studies are recommended for definitive conclusions on COVID-19 vaccine safety in APS.

Keywords:
COVID-19antiphospholipid syndromevaccination

More Related Videos

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-1908:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.0K
Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis06:45

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

14.0K

Related Concept Videos

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
26
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
44
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
20
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
24
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
31
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
957